Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Continuous Exhaled Breath Condensate pH in Mechanically Ventilated Patients
This study is currently recruiting participants.
Verified by University of Virginia, August 2008
Sponsored by: University of Virginia
Information provided by: University of Virginia
ClinicalTrials.gov Identifier: NCT00429637
  Purpose

Given the possible prognostic relationship between exhaled breath condensate pH and clinical symptoms, it is quite plausible that exhaled breath condensate pH can prove useful in the intensive care unit. For example, if exhaled breath condensate pH falls prior to the onset of clinical symptoms, it is likely that it can be useful as an early marker, heralding the onset of various inflammatory lung diseases. Specifically, exhaled breath condensate pH could be used as a safe, non-invasive screening tool for Ventilator Associated Pneumonia. Similarly, just as changes in exhaled breath condensate pH might predict the onset of disease, exhaled breath condensate pH changes might also mark the progression or resolution of disease (e.g. alerting clinicians to possible readiness for extubation). Although such notions are hypothetical, they are beginning to be supported by anecdotal evidence.


Condition Phase
Respiratory Distress Syndrome, Adult
Respiratory Syncytial Virus Infections
Pneumonia
Acute Lung Injury
Phase II

MedlinePlus related topics: Pneumonia Respiratory Syncytial Virus Infections
U.S. FDA Resources
Study Type: Observational
Official Title: Phase 2 Continuous Exhaled Breath Condensate pH in Mechanically Ventilated Patients

Further study details as provided by University of Virginia:

Estimated Enrollment: 120
Study Start Date: December 2004
Estimated Study Completion Date: January 2009
Detailed Description:

The investigators have developed a method of collecting exhaled breath condensate pH continually from ventilated patients, which (1) takes samples from an exhaust port on the outside of the ventilator circuit, and (2) possesses no measurable resistance to the ventilator circuit (and, therefore the sampling procedure in no way affects the patient).

Now, additionally, we have performed the continuous collection process on 10 patients in the intensive care units, none of whom have had any ill effects from the collection process.

The placement of the exhaled breath condensate collection device on the ventilator exhaust port offers a simplified, accurate, and safe method of investigating the relationships between airway pH and various pulmonary inflammatory disease processes in intubated patients of all ages.

In order to further extend our study of airway pH in intubated subjects, we believe it is necessary to obtain more frequent exhaled breath condensate pH measurements from intubated subjects. To that end, we have developed a collection system that will also measure the pH of the collected exhaled breath condensate in a fashion similar to the methodology used for thousands of assays in our laboratory and other laboratories globally. This involves deaeration of the sample to remove carbon dioxide. In the lab environment, this is performed with Argon. In the ICU setting, we will accomplish the same effect by using wall oxygen.

The continuous exhaled breath condensate pH collection and assay system consists of a condenser attached to the exhaust port of the ventilator. The condenser is kept chilled to slightly above freezing temperature by a refrigeration system commonly employed in ICU settings. The collection device stays attached to the exhalation port of the ventilator continuously, for hours to days.

Collected exhaled breath condensate is channeled into two deaeration chambers, through which wall oxygen is bubbled (total flow of 1 liter/min). In the second deaeration chamber, a micro pH electrode is inserted. This pH electrode is attached to a pH recorder that has internal memory that can record essentially an infinite number of measurements, allowing for any length duration of monitoring. This recorder has been evaluated by clinical engineering for radio frequency and other interference and is cleared for hospital use.

After measurement of pH, exhaled breath condensate is channeled into a waste chamber.

The breath condensate collection system is maintained chilled by a "hospital grade" Electri-Cool II model 767 refrigerated cooling system (or near-equivalent) that is clinically approved for use in the intensive care units. This device is approximately 30 cm on a side, and is kept on a wheeled cart out of the way of any clinical activity.

Hypothesis to be Tested: Clearly state the objectives and hypotheses and clearly define the primary and any secondary outcome measures.

  1. Exhaled breath condensate pH will have greater within-hour variability in subjects with lung disease than in subjects intubated for non-pulmonary reasons.
  2. Exhaled breath condensate pH will rise prior to readiness for extubation in infants and toddlers requiring mechanical ventilation for acute bronchiolitis.
  3. A decline in exhaled breath condensate pH or an increase in exhaled breath condensate pH variability will predict the onset of pulmonary inflammatory processes (such as ventilator-associated pneumonia) in those who initially require mechanical ventilation for non-inflammatory reasons.
  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Any intubated patients, aged birth to adulthood, who are on a ventilator in any University of Virginia (UVA) intensive care unit.

Exclusion Criteria:

  • Control subjects may not be taking oral or inhaled steroids or have asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, bacterial or viral pneumonitis, or adult respiratory distress syndrome (ARDS).
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00429637

Contacts
Contact: Brian K Walsh, BS, RRT 434-243-9324 bkw2j@virginia.edu
Contact: John F Hunt, MD 434-243-9324 jhunt@virginia.edu

Locations
United States, Virginia
University of Virginia Recruiting
Charlottesville, Virginia, United States, 22908
Contact: Brian K Walsh, BS, RRT     434-243-9324     bkw2j@virginia.edu    
Contact: John F Hunt, MD     434-243-9324     jhunt@virginia.edu    
Sponsors and Collaborators
University of Virginia
Investigators
Principal Investigator: John F Hunt, MD University of Virginia
  More Information

Study ID Numbers: 11618
Study First Received: January 30, 2007
Last Updated: August 6, 2008
ClinicalTrials.gov Identifier: NCT00429637  
Health Authority: United States: Institutional Review Board

Keywords provided by University of Virginia:
EBC pH
Airway acidification
Condensimetry
ARDS
RSV
ALI
Airway reconstruction

Study placed in the following topic categories:
Virus Diseases
Paramyxoviridae Infections
Respiratory Tract Infections
Respiratory Tract Diseases
Lung Diseases
Respiration Disorders
Respiratory Distress Syndrome, Adult
Acute respiratory distress syndrome
Respiratory Syncytial Virus Infections
Pneumonia

Additional relevant MeSH terms:
RNA Virus Infections
Pneumovirus Infections
Infection
Mononegavirales Infections

ClinicalTrials.gov processed this record on January 16, 2009